Procept BioRobotics price target raised to $47 from $44 at Wells Fargo

Wells Fargo raised the firm’s price target on Procept BioRobotics to $47 from $44 and keeps an Overweight rating on the shares. The firm says it had a chance to speak to Procept’s management after the company pre-announced Q4 results. Its key takeaway is that 2024 consensus is appropriate, and the company is bullish on its capital funnel and handpiece outlook.